<?xml version="1.0" encoding="UTF-8"?>
<p>Precautionary recommendations for patients with immunodeficiencies follow the national guidelines for the general population and include strict hygiene and social distancing measures to limit exposure. A general consensus has been reached to continue established therapies for the immune disorder, even immunosuppressive therapy for autoimmune complications of the underlying disease.
 <xref rid="pai13262-bib-0036" ref-type="ref">
  <sup>36</sup>
 </xref> However, the current pandemic poses an exceptional challenge and safety concern for patients treated with cellular therapies, not only limited to the field of PID.
 <xref rid="pai13262-bib-0037" ref-type="ref">
  <sup>37</sup>
 </xref>
</p>
